Martin Swarbrick

Martin obtained a BSc and PhD in chemistry from the University of Sheffield, UK, and carried out post-doctoral research at the University of Montreal, Canada. He returned to the UK to take up a role in industrial drug discovery and development at GlaxoSmithKline, where he went on to lead medicinal chemistry teams and discovery projects. In 2008, Martin joined CRUK’s Therapeutic Discovery Laboratories (CRUK-TDL) where he led the medicinal chemistry, DMPK, protein sciences and structural biology functions. From June 2021 to June 2025, Martin was Director of R&D Chemistry at Ryvu Therapeutics, and subsequently joined Pharmaron where he is Head of Medicinal Chemistry, Integrated Drug Discovery.